Sumary of Pegloticase plus mycophenolate mofetil reduces antidrug antibodies, boosts efficacy in gout:
- Patients with uncontrolled gout treated with pegloticase and mycophenolate mofetil exhibited reduced probability of developing antibodies to pegloticase and improved response rates at 12 weeks, according to data presented at ACR 2020..
- “The majority of the patients had an enduring response to pegloticase at 24 weeks, even though mycophenolate mofetil was stopped after the first 12 weeks.”.
- “With this in mind, we sought to explore other DMARDs that could be employed, and selected mycophenolate mofetil due to its known safety profile.”.
- To evaluate this strategy, Khanna and colleagues recruited patients from five rheumatology practices (n=35) over 18 months, and randomized them to receive either mycophenolate mofetil 1 gram twice a day or placebo with a run-in of 2 weeks prior to intravenous pegloticase at 8 mg every 2 weeks..
- The primary endpoints included the proportion of patients who achieved and maintained and a serum urate (sUA) 6 mg/dL at 12 weeks, with a secondary endpoint of 6-month durability of immune modulation after discontinuation of mycophenolate mofetil at 12 weeks..
- Additionally, the researchers performed Kaplan-Meier estimates and log-rank test to compare survival curves between groups..
- According to study results, 86% of patients in the mycophenolate mofetil group achieved sUA 6mg/dL at 12 weeks compared with 40% in the placebo…